Legal Opinion
Sanofi-Aventis U.S., LLC v. Fresenius Kabi USA, LLC
Court of Appeals for the Federal Circuit
Decided August 14, 2019No. 2018-1804, 2018-1808, 2018-1809PublishedCited by 21 opinions
1Opinion of the Court
Lourie, Circuit Judge.
Plaintiffs-Appellants (collectively, "Sanofi") appeal from the judgment of the U.S. District Court for the District of New Jersey holding, after a bench trial, claims 7, 11, 14-16, and 26 of U.S. Patent 8,927,592 (the " '592 patent") invalid as obvious. Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA, LLC , No. 14-7869 (D.N.J. Dec. 19, 2017) (" Decision "). Defendants-Cross-Appellants (collectively, "Fresenius") cross-appeal from the same judgment holding claims 1 and 2 of U.S. Patent 5,847,170 (the " '170 patent") not invalid as obvious. Because there was no case or…
2Cases cited28 opinions
- Lujan v. Defenders of WildlifeSupreme Court of the United States · 1992
- United States v. United States Gypsum Co.Supreme Court of the United States · 1948
- Spokeo, Inc. v. RobinsSupreme Court of the United States · 2016
- Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
- Aetna Life Insurance v. HaworthSupreme Court of the United States · 1937
23 more not listed; retrieve them via the Exa API.
3Cited by21 opinions
- Adapt Pharma Operations v. Teva Pharmaceuticals USA, Inc.Court of Appeals for the Federal Circuit · 2022
- Miller Mendel, Inc. v. City of Anna, TexasCourt of Appeals for the Federal Circuit · 2024
- Serta Simmons Bedding, LLC v. Casper Sleep Inc.Court of Appeals for the Federal Circuit · 2020
- Raytheon Technologies Corp. v. General Electric CompanyCourt of Appeals for the Federal Circuit · 2021
- Adapt Pharma Operations v. Teva Pharmaceuticals USA, Inc.Court of Appeals for the Federal Circuit · 2022
16 more not listed; retrieve them via the Exa API.